These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 36198029)

  • 1. Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models.
    Tran KB; Kolekar S; Wang Q; Shih JH; Buchanan CM; Deva S; Shepherd PR
    Mol Cancer Ther; 2022 Dec; 21(12):1777-1787. PubMed ID: 36198029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAF
    Wang N; Wen J; Ren W; Wu Y; Deng C
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):155-164. PubMed ID: 33860836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer.
    Chen G; Gao C; Gao X; Zhang DH; Kuan SF; Burns TF; Hu J
    Mol Cancer Ther; 2018 Apr; 17(4):806-813. PubMed ID: 29167314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
    Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination
    Gunda V; Ghosh C; Hu J; Zhang L; Zhang YQ; Shen M; Kebebew E
    Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898
    [No Abstract]   [Full Text] [Related]  

  • 6. A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib.
    Sinnberg T; Makino E; Krueger MA; Velic A; Macek B; Rothbauer U; Groll N; Pötz O; Czemmel S; Niessner H; Meier F; Ikenberg K; Garbe C; Schittek B
    EBioMedicine; 2016 Jun; 8():132-149. PubMed ID: 27428425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.
    Hong DS; Morris VK; El Osta B; Sorokin AV; Janku F; Fu S; Overman MJ; Piha-Paul S; Subbiah V; Kee B; Tsimberidou AM; Fogelman D; Bellido J; Shureiqi I; Huang H; Atkins J; Tarcic G; Sommer N; Lanman R; Meric-Bernstam F; Kopetz S
    Cancer Discov; 2016 Dec; 6(12):1352-1365. PubMed ID: 27729313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
    Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
    Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines.
    Herr R; Halbach S; Heizmann M; Busch H; Boerries M; Brummer T
    Oncogene; 2018 Mar; 37(12):1576-1593. PubMed ID: 29326440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells.
    Wu Z; Huang M; Gong Y; Lin C; Guo W
    Acta Biochim Biophys Sin (Shanghai); 2018 Apr; 50(4):355-361. PubMed ID: 29534162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
    Prahallad A; Sun C; Huang S; Di Nicolantonio F; Salazar R; Zecchin D; Beijersbergen RL; Bardelli A; Bernards R
    Nature; 2012 Jan; 483(7387):100-3. PubMed ID: 22281684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
    Corcoran RB; Ebi H; Turke AB; Coffee EM; Nishino M; Cogdill AP; Brown RD; Della Pelle P; Dias-Santagata D; Hung KE; Flaherty KT; Piris A; Wargo JA; Settleman J; Mino-Kenudson M; Engelman JA
    Cancer Discov; 2012 Mar; 2(3):227-35. PubMed ID: 22448344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA.
    Ye LF; Huang ZY; Chen XX; Chen ZG; Wu SX; Ren C; Hu MT; Bao H; Jin Y; Wang F; Wang FH; Du ZM; Wu X; Ju HQ; Shao Y; Li YH; Xu RH; Wang DS
    Drug Resist Updat; 2022 Dec; 65():100883. PubMed ID: 36202008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
    Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
    Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study.
    Tan L; Tran B; Tie J; Markman B; Ananda S; Tebbutt NC; Michael M; Link E; Wong SQ; Chandrashekar S; Guinto J; Ritchie D; Koldej R; Solomon BJ; McArthur GA; Hicks RJ; Gibbs P; Dawson SJ; Desai J
    Clin Cancer Res; 2023 Mar; 29(6):1017-1030. PubMed ID: 36638198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
    Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
    Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.
    Kawakami H; Huang S; Pal K; Dutta SK; Mukhopadhyay D; Sinicrope FA
    Mol Cancer Ther; 2016 Dec; 15(12):3015-3027. PubMed ID: 27765849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.
    Al-Marrawi MY; Saroya BS; Brennan MC; Yang Z; Dykes TM; El-Deiry WS
    Cancer Biol Ther; 2013 Aug; 14(8):703-10. PubMed ID: 23792568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF as a target for cancer therapy.
    Dienstmann R; Tabernero J
    Anticancer Agents Med Chem; 2011 Mar; 11(3):285-95. PubMed ID: 21426297
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
    Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.